What's Happening?
Delcath Systems, an interventional oncology company, will participate in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting in Toronto. The company will present its Hepatic Delivery System for percutaneous hepatic perfusion in three
sessions. The presentations will cover user experiences and clinical applications of the system for treating liver metastases from uveal melanoma. Delcath's proprietary products, including the HEPZATO KIT, are designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. The system is approved for use in the U.S. and Europe, offering a targeted approach to liver cancer treatment.
Why It's Important?
Delcath Systems' participation in the SIR meeting highlights advancements in targeted cancer therapies, particularly for liver cancers. The company's Hepatic Delivery System offers a promising treatment option for patients with metastatic uveal melanoma, a condition with limited therapeutic options. By focusing on localized delivery of chemotherapy, the system aims to improve treatment outcomes while reducing side effects. This approach aligns with broader trends in oncology towards personalized and targeted therapies, which have the potential to enhance patient care and expand treatment possibilities for difficult-to-treat cancers.
